---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-077790"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2026-06-25T20:30:12+00:00"
generated_at: "2026-06-25T20:31:56.170208+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Protalix shareholders approve director elections, executive compensation, stock plan increase, auditor ratification

## Summary
- Elected eight directors: each with >28.7M votes; broker non-votes 10.7M for each.
- Advisory approval of executive compensation: 28.4M for, 6.7M against, 0.2M abstain.
- Approved stock plan amendment increasing authorized shares from 17.5M to 21.0M shares (28.2M for, 7.0M against).
- Ratified Kesselman & Kesselman (PwC) as independent auditor for FY2026: 42.96M for, 2.0M against, 1.0M abstain.

## SEC filing metadata
- accession: 0001104659-26-077790
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2026-06-25T20:30:12+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000110465926077790/0001104659-26-077790-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000110465926077790/plx-20260625x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-077790
- JSON: https://secwatch.observer/filing/0001104659-26-077790.json
- Plain text: https://secwatch.observer/filing/0001104659-26-077790.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.